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Design and Analysis of Effects of Triplet Repeat  
Oligonucleotides in Cell Models for Myotonic Dystrophy
Anchel González-Barriga1,2, Susan AM Mulders1,2, Jeroen van de Giessen2, Jeroen D Hooijer1,3, Suzanne Bijl2,  
Ingeborg DG van Kessel1, Josee van Beers1, Judith CT van Deutekom2, Jack AM Fransen1, Bé Wieringa1 and Derick G Wansink1
Myotonic dystrophy type 1 (DM1) is caused by DM protein kinase (DMPK) transcripts containing an expanded (CUG)n repeat. 
Antisense oligonucleotide (AON)-mediated suppression of these mutant RNAs is considered a promising therapeutic strategy 
for this severe disorder. Earlier, we identified a 2′-O-methyl (2′-OMe) phosphorothioate (PT)–modified (CAG)7 oligo (PS58), 
which selectively silences mutant DMPK transcripts through recognition of the abnormally long (CUG)n tract. We present 
here a comprehensive collection of triplet repeat AONs and found that oligo length and nucleotide chemistry are important 
determinants for activity. For significant reduction of expanded DMPK mRNAs, a minimal length of five triplets was required. 
2′-O,4′-C-ethylene-bridged nucleic acid (ENA)–modified AONs appeared not effective, probably due to lack of nuclear 
internalization. Selectivity for products from the expanded DMPK allele in patient myoblasts, an important requirement to 
minimize unwanted side effects, appeared also dependent on AON chemistry. In particular, RNase-H–dependent (CAG)n AONs 
did not show (CUG)n length specificity. We provide evidence that degradation of long DMPK transcripts induced by PS58-type 
AONs is an RNase-H independent process, does not involve oligo-intrinsic RNase activity nor does it interfere with splicing of 
DMPK transcripts. Our collection of triplet repeat AONs forms an important resource for further development of a safe therapy 
for DM1 and other unstable microsatellite diseases.
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Introduction
Myotonic dystrophy type 1 (DM1) is an autosomal dominant, 
trinucleotide repeat expansion disease and the most common 
form of adult onset muscular dystrophy.1–3 The multisystemic 
symptoms are highly variable and involve different tissues 
and organs, including skeletal muscle, heart, brain, eyes, 
reproductive systems, and the gastrointestinal tract. No cure 
to slow or stop the disease process is currently available.
The genetic basis of DM1 is an unstable (CTG)n expan-
sion in the 3′-untranslated region of the DM protein kinase 
(DMPK) gene. Length of the (CTG)n segment is correlated 
with age of onset and severity of disease.1 In the healthy 
population, the CTG repeat is polymorphic in length, with a 
triplet number that ranges from 5 to 37 (mostly below 15),4 
whereas disease alleles may contain between 50 and >2,000 
triplets.1
The DM1 pathogenic mechanism involves an RNA gain-
of-function. Repeat-containing transcripts from the expanded 
allele accumulate in cell nuclei and alter the function of RNA-
binding proteins, whose association with disease has been 
most intensively studied for muscleblind (MBNL) and CUG-
binding protein 1 (CUGBP1).2 In adult DM1 tissue, the result-
ing imbalance in availability of these antagonistic splicing 
regulators causes misregulation of events in which embry-
onic patterns of splicing occur. For example, myotonia and 
insulin resistance, two key features of DM1, may be caused 
by altered splicing of muscle chloride channel and insulin 
receptor transcripts, respectively.2 Also effects on microRNA 
processing and function have been reported.5
Results obtained with DM1 mouse models that inducibly 
express (CUG)n RNA show that features of RNA toxicity 
are reversible,6 strongly suggesting that reducing the level 
of expanded DMPK transcripts will be beneficial to patients. 
In the past decade, different antisense strategies have been 
developed with the intention to eliminate expanded DMPK 
transcripts via either antisense RNA expression, ribozyme 
activity, oligo-mediated RNase-H activity or RNA interference 
(RNAi) technology.7 Reduction of DMPK transcript levels was 
achieved by several of these methods, but selectivity between 
toxic and normal-sized transcripts was generally low.
To be functional and safe for therapeutic use in DM1 
patients, an antisense approach should ideally silence tran-
scripts from the expanded allele only and leave normal-sized 
DMPK transcripts or unrelated transcripts containing (CUG)n 
segments intact. Since length of the (CUG)n repeat is the 
only consistent polymorphic difference between mutant and 
normal DMPK (pre)mRNAs, the repeat tract itself forms an 
attractive therapeutic target. Besides, despite the fact that 
normal and mutant DMPK transcripts are both made in 
the nucleus, (CUG)n length selectivity may be enhanced 
by directing active compounds to this compartment where 
mutant transcripts accumulate after synthesis.
Earlier, we published on the identification and character-
ization of PS58, an antisense oligonucleotide (AON) com-
plementary to the (CUG)n repeat.8 PS58 is a (CAG)7 fully 
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2′-O-methyl (2′-OMe) phosphorothioate (PT)-modified AON, 
which silences expanded (CUG)n transcripts in DM1 cell 
and animal models. Other in vivo AON studies directed at 
the expansion mutation made use of a (CAG)n morpholino 
to interfere with the (CUG)n repeat–MBNL interaction9 or 
LNA (locked nucleic acid)/MOE (2′-O-methoxyethyl)-PT–
type (CAG)n gapmers to recruit RNase-H activity for deg-
radation of (CUG)n-containing transcripts.10 François et al. 
engineered a hU7-(CAG)15-small nuclear RNA which prefer-
entially reduced pathogenic DMPK mRNA in DM1 cells, via a 
yet unknown mechanism.11
Here, we report on specific properties that (CUG)n-di-
rected AONs require for effective knockdown of expanded 
DMPK RNA. Triplet repeat AONs with different chemistries 
and lengths were tested in an unbiased screen for silenc-
ing capacity in a transgenic DM1 cell culture model express-
ing human DMPK (CUG)500 transcripts. AON length and 
nucleotide chemistry appeared to be major parameters 
for therapeutic efficacy. A selection of effective AONs was 
tested in DM1 patient myoblasts. Findings of this study are 
important for transition towards in vivo studies with AONs 
and ultimately for development of a specific AON-mediated 
therapy for DM1. As a first step in support of this transition, 
we report on effects on in vitro complement activation by 
some of these AONs. 
Results
AONs complementary to DMPK’s (CUG)n repeat
A series of triplet repeat AONs that differed in length, chemis-
try, and nucleotide composition was designed and analyzed 
for their ability to silence expanded DMPK transcripts in cul-
tured cells (see AON description in Figure 1a). AONs were 
tested via transfection in the DM500 myoblast–myotube cell 
model.8 The human DMPK (hDMPK) transgene in this model 
is under near-normal myogenic transcriptional control and 
produces hDMPK transcripts bearing a (CUG)500 repeat 
at levels comparable to that of endogenous mouse Dmpk 
(mDmpk) transcripts. It should be noted that mDmpk tran-
scripts contain a CCG(CUG)2(CAG)2CUG sequence instead 
of the generally believed to be uninterrupted (CUG)n seg-
ment found in hDMPK transcripts. Monitoring AON-silencing 
effects was done by northern blotting to follow steady-state 
levels of full-length transgenic hDMPK transcripts and 
possible stable breakdown products. Analysis of endog-
enous mDmpk transcripts was used as a control. Reverse 
transcription-quantitative PCR (RT-qPCR) was included for 
quantitative assessment of expression of defined transcript 
segments.
DNA-based (CAG)n AONs
DNA-type oligonucleotides are known to allow specific 
RNase-H–mediated cleavage of RNA in a DNA–RNA het-
eroduplex.12 For these AONs, several chemical modifications 
have been developed that improve their metabolic stabil-
ity, while maintaining hybridization affinity to target RNA 
and ability to recruit RNase H.13 We tested three DNA-type 
(CAG)7 AONs in DM500 myotubes: PS56, a pure DNA AON; 
PS142, a PT-modified DNA AON; and PS260, a PT-modi-
fied chimeric AON, so called gapmer, comprised of 2′-OMe 
wings on the 5′ and 3′ sides of a DNA gap. DNA AON PS56 
did not show silencing activity (Figure 1a), probably because 
it was quickly degraded inside cells (Supplementary 
 Figure S1). In contrast, PS142 and PS260–both stabilized 
against nuclease breakdown–were able to silence expanded 
hDMPK mRNA for ∼50 and 80%, respectively (Figure 1a,b). 
Endogenous mDmpk mRNA was left intact. A concentration–
response analysis yielded an IC50 (half maximal inhibitory 
concentration) of 0.3 ± 0.4 μmol/l for DNA/PT oligo PS142, 
which is about 1,000-fold lower than that of 2′-OMe/PT lead 
compound PS58 (Figure 1c,  Supplementary  Figure S2 
and ref. 8).
Oligo length and base variations of 2′-OMe AONs
To investigate length as a potential parameter in the per-
formance of PS58-type oligos, we tested a series of fully 
2′-OMe–modified (CAG)n AONs consisting of 4–13 triplets 
in the DM500 myotube culture system. All, except PS251 
(CAG)4, effectively and selectively silenced (CUG)500 
transcripts (>80% efficiency) (Figure 1a,b). A (CUG)7 
2′-OMe sense oligo or 2′-OMe oligos directed against tar-
get sequences in the hDMPK transcript outside the repeat 
did not have a silencing effect (data not shown).8 The lack 
of activity of the (CAG)4 AON is best explained by assuming 
that a minimum oligo length is necessary for effective hybrid-
ization to the (CUG)n target needed for AON activity.
We wondered whether the nature of the nucleotide residue 
at the 5′ or 3′ end of the AON might be crucial for silenc-
ing and tested a repeat-shifted version, 2′-OMe–modified 
(AGC)7 (PS259). PS259 treatment resulted in a significant 
reduction of 85% of (CUG)500 transcripts without silencing 
mDmpk mRNA (Figure 1a).
Finally, a 2′-OMe–modified (CIG)7 AON was tested. The 
inosine residues should enable this AON, PS261, to hybrid-
ize to (CUG)n, (CAG)n, (CCG)n repeats and any combination 
of these triplets. Similar to PS58, PS261 induced 85% reduc-
tion of expanded mRNA (Figure 1a). Notably, endogenous 
mDmpk mRNA was also significantly reduced, albeit with 
only ~35% efficiency. This effect may be best explained by 
binding of (CIG)7 to the CCG(CUG)2(CAG)2CUG sequence 
in mDmpk mRNA. Besides, three low-affinity–binding sites 
were identified that could have a cooperative, additive 
effect (11–13 nucleotides match; not present in hDMPK 
transcripts).
Silencing of expanded hDMPK transcripts by triplet repeat 
2′-OMe AONs in DM500 myotubes was independently con-
firmed by RT-qPCR analysis (Figure 1d). The lower silenc-
ing efficiency measured by RT-qPCR (60–90 versus 85–95% 
detected by northern blotting) is attributed to technical differ-
ences in sensitivity intrinsic to the methods.
Morpholino phosphorodiamidate (CAG)n AONs
Morpholino phosphorodiamidate oligos are uncharged 
AONs widely used as blocking oligos for selective inhibi-
tion of gene expression.14 A (CAG)8 morpholino (PS304) 
was tested for its ability to silence expanded hDMPK RNA 
in DM500 myotubes. The morpholino was coupled to an 
octaguanidine dendrimer (so called Vivo-Porter) to facili-
tate cellular uptake. PS304 treatment caused a 70% reduc-
tion of (CUG)500 transcripts, leaving mDmpk mRNA intact 
(Figure 1a).
www.moleculartherapy.org/mtna
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Figure 1 Collection of triplet repeat AONs tested for their ability to silence expanded hDMPK mRNA in DM500 myotubes. 
(a) Summary of silencing efficiency. Endogenous mDmpk RNA was included as a negative control, since it lacks a pure (CUG)n repeat. 
AONs are grouped according to their main chemical modification: aDNA (capital); RNA (capital, underlined); PT, phosphorothioate linkage 
(*); 2′-OMe, 2′-O-methyl sugar modification (capital, underlined, bold); ENA, 2′-O,4′-C-ethylene-bridged nucleic acid (capital, italics); PMO, 
morpholino phosphorodiamidate (lower case); bCy3-labeled; cCoupled to octaguanidine dendrimer. The means of at least three independent 
experiments for each AON are shown. Dashed line indicates 100% levels (mock samples). (b) Representative northern blots with RNA isolated 
from AON-treated DM500 myotubes probed with a hDMPK and a Gapdh probe. Results of treatment with three AONs (200 nmol/l) or mock 
treatment is shown. (c) Concentration–response curves of PS58 and PS142. DM500 myotubes were treated with a concentration series of 
0.01–500 nmol/l AON (see also Supplementary Figure S2). (d) RT-qPCR analysis of hDMPK RNA levels in DM500 myotubes after treatment 
with a selection of 2′-OMe AONs (200 nmol/l, n ≥ 3). PCR amplicons were located in exon 15, either 5′ or 3′ to the (CUG)n tract. *P < 0.05; 
**P < 0.01; ***P < 0.001. AON, antisense oligonucleotide; Gapdh, glyceraldehyde 3-phosphate dehydrogenase; hDMPK, human DM protein 
kinase; mDmpk, mouse Dmpk; RT-qPCR, reverse transcription-quantitative PCR.
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2′-O,4′-C-ethylene-bridged nucleic acid-modified (CAG)n 
AONs
The bicyclic modification in 2′-O,4′-C-ethylene-bridged 
nucleic acid (ENA) confers strong nuclease resistance and 
high-binding affinity to complementary single-stranded RNA 
(average ΔT
m
 (Δmelting temperature)/modification = 5.5 ver-
sus 1.3 °C for 2′-OMe)15 (Supplementary Figure S1). We 
tested two fully ENA-modified AONs consisting of three and 
four CAG triplets, and three ENA/2′-OMe gapmers of 5, 7, 
and 10 CAGs (PS139-135, Figure 1a). Only treatment with 
PS136 resulted in a small, yet significant reduction (30%) of 
hDMPK RNA expression.
The discrepancy in efficacy between ENA- and 2′-OMe–
modified AONs may be caused by differences in subcellular 
targeting. To verify this possibility, we followed cellular uptake 
and routing of two fluorescently labeled AONs with these 
modifications. For these analyses, we switched to the use 
of DM500 myoblasts, which display a rather flat morphology, 
rendering them more suitable for live cell imaging of AON 
localization than myotubes. Forty minutes after transfection, 
fluorescent PS58 oligo was present in the cell nucleus and sig-
nal intensity further increased up to 60 minutes (Supplemen-
tary Figure S3). This behavior was independent of the type 
of fluorophore used and fluorophore coupling did not affect 
PS58 silencing activity (data not shown). In contrast, labeled 
PS138, as a representative of the ENA AON collection, was 
concentrated in vesicle-like structures and rarely present in 
the nucleus itself. This pattern remained unchanged up to 
48 hours after transfection (data not shown). We conclude 
that lower silencing efficiency of ENA-modified (CAG)n AONs 
observed in this study is due to their inability to reach muscle 
cell nuclei, where most expanded (CUG)n transcripts reside.
Triplet repeat siRNAs
Krol et al.16 reported that (CXG)n triplet repeat hairpins in 
mRNAs are substrates for Dicer and produce short repeat 
RNAs that in turn may act as short-interfering RNAs (siRNAs) 
against complementary repeats. We wanted to investigate 
whether in our cell model expanded hDMPK mRNAs could be 
silenced by introducing synthetic (CAG)n/(CUG)n siRNAs. Two 
different RNA duplexes were transfected in DM500 myotubes, 
PI-01 ((CAG)7/(GCU)7) and PI-02 ((GCA)7/(CUG)7) (Sup-
plementary Table S1). An unrelated siRNA and PS58 were 
included as controls. RT-qPCR analysis demonstrated that 
none of the repeat siRNAs silenced hDMPK mRNA expres-
sion (Figure 2). From our AON stability assay, we conclude 
that it is unlikely that the inability to reduce expanded hDMPK 
transcripts is due to rapid intracellular degradation of the 
chemically unprotected siRNAs (Supplementary Figure S1).
Mouse transcripts containing a small (CUG)n segment
Transcripts that contain a (CUG)n segment, other than 
encoded by the hDMPK transgene, may also serve as targets 
for (CAG)n AONs in DM500 cells. Genes carrying a (CTG)n 
segment are rare, but at least nine transcripts in the mouse 
transcriptome contain a repeat of more than six triplets.8 We 
investigated whether 2′-OMe/PT AONs of variable length and 
sequence ((CAG)5, (CAG)7, (CAG)10, and (CIG)7) acted on 
a subset of these transcripts expressed in DM500 myotubes. 
We analyzed transcript levels by RT-qPCR based on ampli-
cons next to the repeat tracts (Figure 3; primer locations are 
depicted in more detail in Supplementary Figure S4). Ptbp1 
(CUG)6, Txlnb (CUG)9, and Mapkap1 (CUG)26–the longest 
(CUG)n tract in the mouse transcriptome–showed no signifi-
cant changes in expression after AON treatment (Figure 3). 
Note that due to the location of the (CUG)9 tract in the very 
5′ end of the Txlnb gene, no suitable 5′ amplicon could be 
designed to measure Txlnb transcripts.
We also wanted to analyze RNA expression via amplifica-
tion across the (CUG)n triplet repeat. Semi-quantitative RT-
PCR for Ptbp1 and Txlnb transcripts confirmed the RT-qPCR 
findings and showed no significant change in expression 
(Supplementary Figure S5a,b). Remarkably, quantifica-
tion across the Mapkap1 (CUG)26 repeat did record sig-
nificant silencing after AON treatment, especially by PS146 
(CAG)10 (Supplementary Figure S5c). This effect was not 
seen, however, when segments flanking the (CUG)26 tract 
were amplified in the same assay. Also northern blotting, 
visualizing two types of Mapkap1 transcripts as a result 
of alternative polyadenylation17 (Supplementary Figure 
S4), revealed only a minor reduction in RNA expression, 
whereas western blotting revealed no significant changes 
in Mapkap1 protein expression (Supplementary Figure 
S5d,e). We therefore decided that PCR-based quantifica-
tion should not rely on amplification across a medium-sized 
(CUG)n tract.
Given these observations, we wanted to exclude the possi-
bility that traces of AONs that might still be present in purified 
RNA samples would interfere with RT-PCR analysis. Using a 
hybridization–ligation method, we determined that free AON 
concentration in our RNA preparations was <0.2 nmol/l. To 
rule out interference of (CAG)n AONs with RT or PCR ampli-
fication, untreated DM500 RNA samples were spiked with 
0.1–10 nmol/l PS147, PS58 or PS146 and correspondingly 
used in RT-PCR analysis. Presence of AONs during RT-PCR 
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Figure 2 RT-qPCR analysis of hDMPK (CUG)500 RNA levels 
in DM500 myotubes after treatment with siRNAs (50 nmol/l) 
targeting the (CUG)n repeat (n = 6). PS58 (50 nmol/l) was 
used as a control. Sequences of PI-01 ((CAG)7/(GCU)7 duplex), 
PI-02 ((GCA)7/(CUG)7 duplex), and control siRNA are listed in 
Supplementary Table S1. **P < 0.01. hDMPK, human DM protein 
kinase; RT-qPCR, reverse transcription-quantitative PCR; siRNA, 
short-interfering RNA.
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amplification did not have an effect on Mapkap1 (CUG)26 
levels nor on quantification of hDMPK (CUG)500 RNA (Sup-
plementary Figure S6). In sum, we conclude that transcripts 
containing small (CUG)n tracts were largely unaffected by 
the (CAG)n and (CIG)n repeat oligos tested.
Mouse transcripts carrying a small (CAG)n segment
To examine the possibility that oligo-mediated hDMPK RNA 
breakdown would generate short (CUG)n RNAs that in turn 
might act as siRNAs on complementary (CAG)n transcripts 
(compare, ref. 16), we measured levels of mouse transcripts 
with a small (CAG)n segment: Sec24b (CAG)15, Hcn1 
(CAG)7+(CAG)20, and Nr3c1 (CAG)17. After treatment with 
PS147, PS58, PS146, and PS261; no significant change 
in expression of any of these transcripts was detectable by 
RT-qPCR analysis (Figure 4) ruling out an indirect effect of 
(CAG)n AONs on transcripts bearing a (CAG)n segment in 
the transcriptome.
(CUG)n length selectivity in DM1 patient myoblasts
A safe, antisense strategy for DM1 should differentiate 
between expanded and normal-sized hDMPK transcripts. 
To test this requirement, we used two DM1 myoblast cul-
tures: one expressing hDMPK transcripts with 21 (normal) 
and 200 (mutant) triplets (abbreviated 21/200) and another 
with 5 and 1,400 CUG triplets (abbreviated 5/1,400).18 Activi-
ties of three 2′-OMe AONs, PS147, PS58, and PS146 were 
examined in these cultures, with use of northern blotting to 
discriminate between normal and mutant hDMPK RNA. The 
three pure 2′-OMe/PT AONs behaved equally (Figure 5a): 
levels of (CUG)1400 and (CUG)200 transcripts were strongly 
decreased (65–95%). (CUG)21 transcripts appeared less 
susceptible to breakdown (45–55%) and as expected, 
(CUG)5 hDMPK mRNA was left intact. Silencing efficacy sig-
nificantly correlated with the number of CUG triplets in the 
transcripts (Figure 5b).
Western blot analysis showed that silencing of hDMPK 
transcripts by PS146 (CAG)10 resulted in around 50% loss of 
DMPK protein after 72 hours in 21/200 myoblasts (Figure 6). 
No effect of PS147 (CAG)5 or PS58 (CAG)7 treatment was 
observed at this time point.
Human transcripts containing a small (CUG)n segment
Also in the human transcriptome (CUG)n tracts are relatively 
rare.8,19 Effects of a subset of 2′-OMe/PT AONs on tran-
scripts bearing a (CUG)n repeat expressed in 5/1,400 myo-
blasts were examined for two transcripts: BPGM (CUG)8 and 
MAP3K4 (CUG)10 by RT-qPCR. No reduction of BPGM tran-
scripts was detected after treatment with PS147 and PS146, 
whereas only a small effect was seen with PS58 (25% reduc-
tion) (Figure 7a). Similar effects for BPGM (CUG)8 were 
detected in 21/200 myoblast cultures (data not shown).
Total MAP3K4 mRNA levels were not affected by 2′-OMe 
AON treatment (Figure 7b). A conspicuous observation was 
made with regard to an effect on MAP3K4 pre-mRNA pro-
cessing. Analysis of the fate of alternative exon 17,20 which 
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Figure 3 Expression of three mouse transcripts, carrying a small (CUG)n repeat, after transfecting DM500 myotubes with a selection 
of AONs. (a) Ptbp1 (CUG)6, (b) Txlnb (CUG)9, and (c) Mapkap1 (CUG)26. RNA levels were analyzed by RT-qPCR amplifying segments 
flanking the triplet repeat (n = 3). Schemes illustrate exon–exon junctions, locations of PCR primers, and amplicons. Dashed lines indicate 
100% levels (mock samples). AON, antisense oligonucletide; RT-qPCR, reverse transcription-quantitative PCR.
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Figure 4 Analysis of expression levels of three mouse 
transcripts, containing a (CAG)n repeat, in DM500 myotubes 
after transfection with a selection of AONs. (a) Sec24b (CAG)15, 
(b) Hcn1 carrying a (CAG)7 and a (CAG)20 repeat located close 
together (see Supplementary Figure S4), and (c) Nr3c1 (CAG)17. 
Expression was analyzed by RT-qPCR amplifying segments flanking 
the triplet repeat (n = 3). Schemes illustrate exon–exon junctions, 
locations of PCR primers, and amplicons. Dashed lines indicate 
100% levels (mock samples). AON, antisense oligonucletide; 
RT-qPCR, reverse transcription-quantitative PCR.
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contains the short (CUG)10 repeat that might serve as tar-
get, revealed that PS146 (CAG)10 was able to enhance exon 
17 skipping (Supplementary Figure S7). Effects on alterna-
tive splicing by shorter (CAG)n oligos were only minor.
Investigating potential mechanisms of expanded hDMPK 
transcript silencing
We wondered whether exon skipping could also be the 
underlying or initiating mechanism of PS58-induced silencing 
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Figure 7 Analysis of expression of two transcripts, each 
containing a small (CUG)n repeat, in DM1 patient myoblasts 
(5/1400) after transfection with a selection of AONs. RNA levels 
of (a) BPGM (CUG)8 and (b) MAP3K4 (CUG)10 were measured 
by RT-qPCR (n = 3). Schemes illustrate exon–exon junctions and 
locations of PCR primers and amplicons. Dashed lines indicate 
100% levels (mock samples). *P < 0.05; **P < 0.01. AON, antisense 
oligonucleotide; RT-qPCR, reverse transcription-quantitative PCR.
0
M
oc
k
M
oc
k
PS
14
7 (
CA
G)
5
PS
14
7 (
CA
G)
5
PS
58
 (C
AG
)7
PS
58
 (C
AG
)7
PS
14
6 (
CA
G)
10
PS
14
6 (
CA
G)
10
PS
26
0 (
CA
G)
7
PS
26
0 (
CA
G)
7
21/200 5/1400
25
50
m
R
N
A 
le
ve
l (%
)
75
100
Normal Expanded
Normal
GAPDH
Exp
0
25
50
75
100
P = 0.07
P = 0.07
*
*
***
******
***
***
***
*
**
**
**
**
*
0
10 100
Number of CTG triplets
1,000
25
50
m
R
N
A 
le
ve
l (%
)
75
100
PS147
PS58
PS146
PS260
b
a
Figure 5 (CUG)n length selectivity in DM1 myoblasts. (a) Human 
myoblasts expressing either hDMPK (CUG)21 and (CUG)200 
transcripts (21/200) or hDMPK (CUG)5 and (CUG)1400 transcripts 
(5/1400) were treated with a selection of CAG AONs. Northern blot 
analysis indicated that expanded hDMPK transcripts (“Exp”, arrow 
heads) were efficiently silenced by all AONs. (CUG)21 transcripts 
(“Normal”, double arrow heads) were moderately silenced. Only 
RNase-H recruiting PS260 substantially degraded (CUG)5 transcripts 
(“Normal”, double arrow head). One representative blot of three 
independent experiments is shown for each cell culture. Quantification 
of signals is summarized in the graphs at the bottom.  *P < 0.05; 
**P < 0.01; ***P < 0.001. (b) A significant correlation was demonstrated 
between the number of CTG triplets and silencing activity of PS147, 
PS58, and PS146 (P < 0.05, Pearson’s correlation, r = −0.98), but 
not PS260. AON, antisense oligonucleotide; GAPDH, glyceraldehyde 
3-phosphate dehydrogenase; hDMPK, human DM protein kinase.
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of expanded hDMPK transcripts. hDMPK pre-mRNAs are 
subject to extensive alternative splicing and events involving 
final exon 15, in which the (CUG)n tract is located, have been 
reported.21,22 For analysis of fate of different hDMPK RNA 
segments in presence of AONs, we used a transcript scan-
ning RT-qPCR approach for amplicons along the expanded 
hDMPK transcript in DM500 myotubes. Amplicons were 
designed in the 5′ end of the gene (exon 1–exon 2, exon 4– 
exon 5) and on either side of the (CUG)n tract in exon 15 
(Figure 8). No significant differences were found in signal 
strength for any of these hDMPK segments (70–85% reduc-
tion for all segments across the transcript, compared with 
mock-treated samples). This finding indicates that PS58-
induced skipping of the (CUG)n tract during hDMPK pre-
mRNA splicing is unlikely to be mechanistically involved.
Test tube incubation of radioactively labeled, in vitro-
 transcribed (CUG)90 RNA with a concentration series of 
PS58 (CAG)7 caused a mobility shift illustrating direct oligo–
RNA association (Supplementary Figure S8). Similar shifts 
were seen after incubation of different (CAG)n and (CUG)n 
AONs with (CUG)90 or (CAG)90 RNAs (Supplementary Fig-
ure S8). To exclude that triplet repeat 2′-OMe AONs had an 
intrinsic RNase activity, similar to ribozymes or DNAzymes,23 
(CUG)n RNA was incubated with a series of different AONs in 
the presence of various concentrations of Mg2+, Mn2+ or Zn2+ 
(Supplementary Figure S8; data not shown). No (CUG)n 
breakdown products could be detected, indicating that under 
the conditions tested, none of these AONs displayed RNase-
like activity when complexed to (CUG)n RNA.
Using the same (CUG)90 RNA template, we could con-
firm that PS58, a fully modified 2′-OMe AON, was unable to 
induce RNase-H–mediated degradation of expanded (CUG)n 
transcripts in vitro (Supplementary Figure S8). As posi-
tive controls, we used DNA-type AON PS142 and gapmer 
PS260, both of which were able to recruit RNase-H to cleave 
(CUG)90 RNA. Activity of gapmer PS260 was also examined 
in human myoblasts, but with an apparent lack of specificity 
(Figures 5 and 6). More than 60% of both expanded and 
normal-sized hDMPK transcripts were degraded. Similar lack 
of specificity was observed for BPGM (CUG)8 and MAP3K4 
(CUG)10 RNAs, for which a 40% reduction in steady-state 
copy number was observed (Figure 7). Since the MAP3K4 
exon 17+ variant and the exon 17− variant (which lacks the 
AON target site) were equally reduced by PS260, we con-
clude that RNase-H–dependent degradation must have 
occurred in the nucleus, before exon 17 splicing (Supple-
mentary Figure S7).
Complement activation by triplet repeat AONs
All triplet repeat oligos were well tolerated by cells in culture 
and essentially no toxic effects on growth or behavior were 
observed (data not shown). A well-known toxic side effect of 
AONs in vivo, especially PT-modified versions, is activation of 
the complement pathway.24 As a prelude to later preclinical 
studies in animals and humans, we tested a selection of our 
PT-modified AONs with different chemistries and sequences 
for their ability to activate complement in plasma in vitro: full 
2′-OMe (PS58, PS146, PS147, PS261), chimeric 2′-OMe/
DNA (PS260), and pure DNA (PS142). A first generation oli-
gonucleotide known to activate the complement pathway was 
included as a positive control.25 Formation of complement split 
products C3a (marker for the classical and alternative path-
way) and Bb (marker for the alternative complement pathway) 
was measured in plasma from cynomolgus monkeys and 
humans after addition of AONs (Supplementary Figure S9). 
In particular, PS261 (CIG)7, and to a lesser extent PS146, 
PS147, and PS260, caused a significant dose-dependent 
increase in the concentration of Bb in cynomolgus plasma. 
Only PS261 and PS260 activated C3a formation in human 
plasma. Other AONs showed no significant or minor effects.
Discussion
This study demonstrates that a range of triplet repeat AONs is 
capable of silencing expanded hDMPK transcripts. The long 
(CUG)n target that characterizes toxic hDMPK transcripts is a 
special RNA sequence in the sense that it can form a  stem-loop 
structure that folds almost like an antiparallel double-stranded 
helix, despite the periodic U•U mismatches.26 We conclude 
that the thermodynamically stable hairpin structure, known 
to sequester members of the MBNL protein  family, does not 
hamper accessibility of antisense repeat AONs, when in the 
cellular context. The (CUG)n repeat, whose length differs 
between normal-short and mutant-expanded hDMPK tran-
scripts, is therefore an attractive therapeutic target.
Chemical modifications of the sugar phosphate backbone 
of AONs serve to confer resistance against nucleases to 
extend cellular half-life.13 The silencing activity of modified 
AONs PS142 and PS260 versus the inability of pure DNA 
AON PS56 to induce breakdown clearly illustrates the rela-
tionship between stability and efficacy. Oligo chemistry may 
also determine nucleocytoplasmic distribution of AONs. As 
target transcripts in DM1 are concentrated in the nucleus, 
an AON must be capable to enter this compartment to 
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become useful. Microscopic evidence is provided that 
ENA-modified AONs remain in vesicular structures and 
only inefficiently reach the nucleus, rendering them a poor 
choice for repeat-directed antisense DM1 strategies. We 
have no simple explanation for this finding, as similarly 
modified 2′-OMe RNA/ENA chimeras have shown activity 
in the nucleus during exon skipping for Duchenne muscular 
dystrophy.27 Effects of nucleotide sequence on subcellular 
oligo localization cannot be excluded at this point. Also the 
type of cell model and transfection method used may have 
an effect.
Not all types of AONs were equally efficient and specific, 
but as we compared only triplet repeat oligos here, some 
conspicuous observations are worth mentioning. First, as an 
explanation for the failure of (CUG)n/(CAG)n triplet repeat 
siRNAs to induce an RNAi response, we assume that a com-
bination of chemistry and oligo sequence must be respon-
sible. The poor performance of the two duplexes tested can 
be the result of unfavorable subcellular distribution of siR-
NAs, although the RNAi machinery is known to be active in 
the nucleus.28 Alternatively, the (CUG)n RNA hairpin may be 
insufficiently accessible to certain components of the RNAi 
pathway in our myogenic cell model. Very recently, a com-
parable triplet repeat siRNA was successfully tested in vivo 
in skeletal muscle in a mouse model for DM1. (CUG)220 
expanded RNA and also Txlnb (CUG)9 transcripts were 
reduced, but not Mapkap1 (CUG)25 RNA.29
Second, oligo PS261 (CIG)7 was initially considered a 
promising new lead compound, because of its predicted ability 
to bind to (CUG)n as well as (CAG)n transcripts, with poten-
tial for treatment of DM1 and polyQ diseases like Hunting-
ton’s disease and several spinocerebellar ataxias. From the 
complement activation assay we learned, however, that this 
AON activated the complement cascade, rendering it a less 
favorable candidate for further development. Virtually none of 
the other AONs showed major adverse effects in vitro, with 
the best performing oligo being PS58. Screening for toxicity 
profiles in animals in vivo will be a logical next step.
Third, RNase-H recruiting AON PS260 appeared to have 
prominent silencing capacity, but also suffered of lack of 
target specificity. Further characteristics of these DNA-type 
AONs will be discussed below in the context of mechanistic 
considerations.
The main focus of our study had to do with AONs based 
on 2′-OMe/PT chemistry. For these AONs, we demonstrated 
that oligo length may provide a means to introduce selectivity 
between expanded transcripts from a mutated hDMPK allele 
and RNA containing a normal, short (CUG)n tract. The short-
est variant in our series of 4–13 CAG triplets was unable to 
knockdown expanded transcripts in DM500 myotubes. The 
hybridization strength of the four CAG triplet AON may have 
been insufficient for a stable interaction with a (CUG)n seg-
ment in the living cell, even though the theoretical T
m
 for this 
interaction is around 39 °C.
AONs longer than four triplets efficiently silenced transgenic 
(CUG)500 transcripts. Significant (CUG)n repeat length-
dependent activity in patient cells was displayed by (CAG)5, 
(CAG)7, and (CAG)10 2′-OMe/PT AONs. Between them they 
showed no significant difference in activity towards normal-
sized hDMPK transcripts: (CUG)5 transcripts, expressed 
by ~40% of the Caucasian population,4 were left intact and 
(CUG)21 transcripts were ~50% reduced by all three AONs. 
In contrast, differential effects were observed at the DMPK 
protein level, which might indicate a correlation with transla-
tion efficiency of remaining hDMPK transcripts. It should be 
noted that we cannot predict at the moment whether partial 
reduction of normal-sized transcripts will have any adverse 
consequences. We know that Dmpk knockout mice have rela-
tively mild phenotypes,30 hence a low level of remaining Dmpk 
protein might be sufficient to protect functional and structural 
integrity of cells in which it is expressed. Another still unre-
solved issue is the minimum efficacy needed for a beneficial 
effect. Partial suppression of toxic (CUG)n RNA may already 
be of clinical relevance in DM1 patients.
Expression of genes with a small (CTG)n repeat in myo-
genic cells was essentially unchanged upon treatment with 
2′-OMe/PT AONs, except for MAP3K4. PS146 (CAG)10 
enhanced skipping of MAP3K4 exon 17 in which the 
(CUG)10 repeat is located. This (CUG)10 repeat is unusual 
as it is located in an alternative exon, where it might function 
as an exon-splicing enhancer.31 To what extent exon 17+ and 
exon 17− transcript variants contribute to protein production 
is unknown. More importantly, it is unclear whether a shift in 
MAP3K4 isoform ratio would have a biological effect. Nothing 
is known about functional differentiation generated by inclu-
sion of the 50 amino acid stretch encoded by in-frame exon 
17 (including 10 alanines encoded by the repeat tract). The 
minor shift in MAP3K4 variant ratio induced by smaller (CAG)n 
AONs is essentially within the normal variation observed in 
mock samples. Note that since splicing is a nuclear process, 
we can conclude that PS146 (CAG)10 must have been active 
inside the nucleus.
It is difficult to reconcile all observations regarding Map-
kap1 (CUG)26 transcripts. First, as also seen with MAP3K4 
transcripts, oligo length is an important parameter for AON 
activity and side effects seem to intensify with increased oligo 
length. Second, we provide ample evidence that our oligos 
did not interfere with RT-PCR quantification. Third, we pro-
pose that special care should be taken with RNA quantifi-
cation based on amplicons covering a triplet repeat of >10 
units. These amplicons will never meet requirements for 
RT-qPCR analysis, but they may also be useless in semi-
quantitative RT-PCR. For that reason, we generally used 
segments outside the repeat region for PCR quantification. 
Similar warnings regarding RT-PCR and use of AONs have 
been issued by others.32 Given the location of the (CTG)26 
repeat in between two alternative polyadenylation sites of the 
Mapkap1 gene,17 we cannot exclude length-dependent AON 
effects on splicing, transcription termination or polyadenyla-
tion. Clearly, more work is needed to be able to unequivocally 
interpret these data.
What do we know about the molecular mechanism under-
lying silencing activity of hDMPK transcripts by triplet repeat 
AONs examined here? Although the goal of this study was 
not to identify distinct pathways or describe novel interfer-
ence principles, our findings provide important new insight in 
potential activities of triplet repeat AONs.
In a series of simple biochemical test tube experiments, 
we first investigated whether triplet repeat 2′-OMe/PT AONs 
might carry intrinsic endoribonuclease activity, similar to 
www.moleculartherapy.org/mtna
Triplet Repeat Oligos for Myotonic Dystrophy 
González-Barriga et al.
9
ribozymes or DNAzymes.23 In none of the experiments 
RNase activity was detected. Although we also tested several 
cell-free or protein-free conditions (data not shown), it cannot 
be excluded that the right cellular reaction conditions were 
not fully reproduced.
We provide evidence that PS260, a (CAG)7 gapmer, effi-
ciently reached various (CUG)n RNA targets, irrespective 
of repeat length, and recruited endogenous RNase-H for a 
first endonucleolytic cleavage. We expect that unprotected 
5′ and 3′ RNA segments will be degraded after initial cleav-
age by conventional exonucleases as part of the quality con-
trol system in the cell.33 Surprisingly, PS260 showed only 
little selectivity between expanded and normal-sized hDMPK 
transcripts in patient cells, suggesting that either RNase-H 
activity took place in both the nucleus and the cytosol, or that 
degradation already occurred swiftly, during or shortly after 
RNA synthesis in the nucleus. Our observations contrast 
with a report that an LNA-based repeat gapmer did cleave 
hDMPK (CUG)40, but not (CUG)12 transcripts;10 and also 
with a study in which a (CAG)6 LNA gapmer did not reduce 
CASK (CUG)16 RNA.34 The reason for these discrepancies 
should probably be found in oligo chemistry, concentration or 
model system used.
Nucleotide analogs like morpholinos or modifications like 
2′-OMe do not support RNase-H–dependent degradation. 
These AONs must therefore use distinct pathways, explain-
ing why PS58, a 2′-OMe/PT (CAG)7 AON, and PS260, dis-
played differential (CUG)n length-dependent silencing.
The RNAi pathway is unlikely to be involved in activity of 
fully 2′-OMe/PT AONs or (CAG)n morpholinos. Imperfect 
hybrids of 2′-OMe/PT or morpholino (CAG)n AONs, or perfect 
hybrids that these AONs may form with (CUG)n transcripts, 
will not be recognized by the RNAi machinery.35–37 Further-
more, the size of the shortest effective AON (15 nucleotides) 
and tolerated 5′ modifications like a fluorescent group (as in 
FAM-PS58) or a peptide (data not shown) render involvement 
of the RNAi pathway highly unlikely.38,39 Also, we did not find 
evidence for AON-induced processing of expanded hDMPK 
transcripts into (CUG)n siRNAs that could trigger degrada-
tion of (CAG)n transcripts.
Fully 2′-OMe/PT-modified AONs, like PS58, and morpholi-
nos are usually designed and employed to serve as block-
ing oligos to modulate splicing or prevent translation.13,40 
As discussed above, PS146, a 30 nucleotide long 2′-OMe/
PT AON, exhibits splicing modulating activity. We could not 
detect a similar activity of (CAG)n AONs towards hDMPK 
(CUG)500 transcripts. The most logical explanation for this 
observation is the location of the (CUG)n repeat in the final 
exon of the hDMPK gene. The only reported splice accep-
tor, located around 35 nucleotides 3′ of the (CUG)n tract, is 
only rarely used22,41 and probably too weak to be amenable 
to manipulation.
A (AGC)8A morpholino reportedly blocked Mbnl1 protein 
binding to transgenic (CUG)250 transcripts in a mouse model 
for DM1-related RNA toxicity.9 In that study, cytoplasmic lev-
els of expanded transcripts raised upon treatment, but the 
total amount of (CUG)250 transcripts was ~50% reduced. A 
comparable reduction was reported for expanded Huntingtin 
(CAG)n RNA using a (GCT)6G LNA-type blocking oligonu-
cleotide.42 The molecular mechanism underlying the activity 
of AGC morpholino is unknown, but it was suggested that the 
displacement of expanded transcripts to the cytoplasm may 
have induced hDMPK mRNA decay. We propose that a simi-
lar mechanism may be at play for our (CAG)n morpholino and 
the 2′-OMe/PT AONs examined here. Alternatively, this class 
of AONs may activate a yet to be identified RNase or RNA 
decay program in nucleus or cytoplasm. Our current working 
hypotheses are that the interaction between (CAG)n AONs 
and the (CUG)n repeat attracts proteins involved in RNA 
degradation or that AON binding displaces RNA-protecting 
proteins resulting in naked RNA, which is extremely sensi-
tive to RNases. Further detailed studies into these interesting 
possibilities are warranted. 
In sum, we provide further evidence that the expanded 
(CUG)n segment in hDMPK mRNA, being the product from 
the only known mutation in DM1, forms an attractive target for 
AON therapy. For development of future treatment modalities, 
chemical structure and oligo length in combination with the 
rather special sequence content needed—i.e., the comple-
mentary (CAG)n repeat character—have now been identi-
fied as crucial determinants. By extrapolation of findings, our 
results also open up interesting possibilities for therapy of 
other triplet repeat diseases.
Materials and methods
Cell culture. Immortalized DM500 myoblasts were derived 
from DM300-328 mice43 and cultured and differentiated to 
myotubes as described.8 Human DM1 myoblast lines were 
derived and cultured as described.18
Oligonucleotides. AONs and siRNAs were complementary 
to the (CUG)n repeat. Their sequence and chemistry are 
listed in Figure 1a and Supplementary Table S1, except 
for control oligos scrambled-PS58: 5′-CAGAGGACCACC 
AGACCAAGG-3′; and PS57: 5′-CUGCUGCUGCUGCUGCU 
GCUG-3′ (both fully 2′-OMe/PT-modified). All AONs and siR-
NAs were provided by Prosensa (Leiden, The Netherlands), 
except morpholino PS304, which was purchased coupled to 
an octaguanidine dendrimer from Gene Tools (Philomath, 
OR) and control siRNA, purchased from Thermo Scientific 
Dharmacon (Lafayette, CO).
Oligotransfection. AONs were transfected using polyethyle-
neimine (ExGen 500; Fermentas, Glen Burnie, MD) according 
to the manufacturer’s instructions. Typically, 5 μl polyethyl-
eneimine/μg AON was added at a final AON concentration of 
200 nmol/l in differentiation medium to myotubes on day 5 of 
myogenesis or in Opti-MEM (Invitrogen, Carlsbad, CA) to myo-
blasts. For concentration–response experiments, oligo con-
centrations between 0.01 and 500 nmol/l were applied. Four 
hours later, fresh medium was supplemented to a maximum 
volume of 2 ml medium/well. Medium was changed 20 hours 
later. RNA was isolated 48 hours after start of transfection.
PS304 was tested following the protocol above with the 
exception that no transfection reagent was used.
siRNAs were administered twice (on subsequent days: day 
4 and 5 of myogenesis) using a Lipofectamine 2000-based 
transfection protocol (Invitrogen) according to the manufac-
turer’s instructions, at a final concentration of 50 nmol/l. Four 
hours following addition of the transfection mix and 24 hours 
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after start of the second transfection, medium was changed. 
RNA was isolated 48 hours after the second transfection.
Oligo stability. AONs (7.5 pmol) were radioactively labeled 
by T4 polynucleotide kinase in the presence of [γ-32P]-ATP 
and then purified on G50 columns followed by ethanol 
precipitation.
DM500 myoblast whole cell extract was prepared by 
scraping ~1 × 106 cells per well in phosphate-buffered saline 
(PBS) containing 1 mmol/l EDTA. Cells were collected via 
centrifugation (1,000 rpm, 5 minutes), packed cell volume 
was estimated and cells were resuspended in 1× packed cell 
volume of 10 mmol/l Tris-HCl; pH 8.0, 1.5 mmol/l MgCl2, 10 
mmol/l KCl, 1 mmol/l DTT and 1× Protease Inhibitory Cock-
tail (Roche, Almere, The Netherlands). Cell suspensions 
were placed on ice for 15 minutes and homogenized using 
a pestle. Whole cell lysate was collected after centrifugation 
(14,000g, 10 minutes).
AONs (~2 pmol) were incubated with 5 μl whole cell lysate 
at 37 °C for 0, 3 or 24 hours, reaction was stopped by adding 
140 mmol/l sodium acetate; pH 5.0, phenol/CHCI3 and water 
phase was collected (14,000g, 10 minutes, 4 °C). Oligo was 
precipitated by the addition of three volumes of ethanol. The 
oligo precipitate was washed with 70% (vol/vol) ethanol, air 
dried and dissolved in sample buffer (75% deionized forma-
mide, 25% glycerol). Samples were loaded on a 12% (wt/vol) 
acrylamide/bisacrylamide (37.5:1) denaturing urea (8 mol/l) 
PAGE gel in 1× MOPS buffer. After running, gels were dried 
at 70 °C for 2 hours and exposed to X-ray film (X-Omat AR; 
Kodak, Rochester, NY).
RNA isolation. RNA was isolated using the Aurum Total RNA 
Mini Kit (Bio-Rad, Hercules, CA), according to the manufac-
turer’s protocol.
Northern blotting. Northern blotting was done as described.8 
Random-primed 32P-labeled human DMPK (2.6 kb cDNA), rat 
Gapdh (1.1 kb cDNA), and mouse Mapkap1 (1.1 kb cDNA) 
probes were used. Signals were quantified by phospho-im-
ager analysis (GS-505 or Molecular Imager FX; Bio-Rad) and 
analyzed with Quantity One (Bio-Rad) or ImageJ software. 
Gapdh levels were used for normalization. RNA levels of con-
trol samples were set at 100%.
RT-PCR. Primer sets for PCR were designed using Primer-
BLAST44 in the National Center for Biotechnology Information 
database and validated in silico using OligoAnalyzer 3.145 to 
prevent formation of hairpins and dimers during amplifica-
tion. Resulting products were visualized on agarose gels and 
sequenced to verify identity and triplet repeat length. Primer 
sequences are listed in Supplementary Table S2.
For RT, typically 0.5 μg RNA was subjected to cDNA syn-
thesis using the SuperScript first-strand synthesis system 
with random hexamer primers in a total volume of 20 μl. 
For RT-PCR experiments in presence of AONs, AONs were 
added to the RNA to reach the indicated final concentration 
and incubated for 15 minutes on ice before starting the RT 
reaction.
For semi-quantitative RT-PCR, 1 μl of cDNA preparation 
was used in a PCR according to standard procedures. In RT− 
control experiments, reverse transcriptase was omitted. The 
signal for β-actin was used for normalization. Cycle number 
was 18 for β-actin and 22-31 for other primer sets. PCR prod-
ucts were analyzed on 1.5–2.5% agarose gels stained by 
ethidium bromide. Quantification of signals was done using 
Labworks 4.0 software (UVP BioImaging Systems, Cam-
bridge, UK). Values for control samples were set at 100%.
For RT-qPCR, all procedures were performed following the 
Minimum Information for Publication of Quantitative Real-Time 
PCR Experiments (MIQE) guidelines.46 Amplification efficiency 
of primer sets was determined using standard curves (serial 
dilutions; tenfold to 5,000-fold range). Primers sets displaying 
<90% efficiency in product amplification were ruled out and 
redesigned. cDNA preparations (see RT reaction above) were 
diluted 200–500-fold to avoid PCR inhibition by RT components; 
3 μl of this dilution was mixed in a final volume of 10 μl contain-
ing 5 μl 2X Sybr Green mix (Roche Applied Science, Almere, 
The Netherlands) and 400 nmol/l of each primer using the 
CAS-1200 automated pipetting system (Corbett Life Science/
Qiagen, Venlo, The Netherlands). No template control and no 
reverse transcriptase control (RT−) were included in each qPCR 
run to detect possible contaminations. Samples were analyzed 
using the Rotor-Gene 6000 (Corbett Life Science) or CFX96 
Real-time System (Bio-Rad). A melting curve was obtained for 
each sample to confirm single product amplification. Relative 
mRNA levels were calculated using the ΔΔCt method.47 Both 
Actb and Gapdh were used for normalization. We validated that 
these reference genes were not affected by the treatment and 
had an optimal M stability value48 under all experimental condi-
tions. Values of control samples were set at 100%.
AON hybridization–ligation assay. PS58 concentrations were 
determined by a hybridization–ligation assay as published 
by Yu et al.49 with a few modifications: Template DNA probe 
(5′-GAATAGACGCTGCTGCTGCTGCTGCTGCTG-biotin-3′) 
and ligation DNA probe (5′-P-CGTCTATTC-digoxigenin 
(DIG)-3′) were used. Samples were incubated with the tem-
plate probe (50 nmol/l) at 37 °C for 1 hour and hybridized 
samples were transferred to streptavidin-coated plates. Sub-
sequently, plates were washed four times and the DIG-labeled 
ligation probe (2 nmol/l) was added and incubated for 30 min-
utes at ambient temperature. DIG label was detected using 
an anti-DIG-POD (1:7,500; Roche Diagnostics, Almere, The 
Netherlands), visualized with a 3,3′,5,5′-tetramethylbenzidine 
substrate (Sigma Aldrich, Zwijndrecht, The Netherlands). 
The reaction was stopped using maleic acid (345 mmol/l; 
Sigma Aldrich). Absorption was measured at 450 nm using a 
BioTek Synergy HT plate reader (Beun de Ronde, Abcoude, 
The Netherlands). All samples and calibration curves were 
diluted (fit to criteria of the assay) in PBS. Absorption was 
read against a calibration curve of PS58 in PBS. A sample 
containing only PBS was used as correction for background.
Live cell imaging. DM500 myoblasts were cultured on gelatin-
coated glass-bottom Willco dishes (Willco Wells, Amsterdam, 
The Netherlands). Cells were analyzed directly after addi-
tion of the transfection mix containing FAM-PS58 or Cy3-
PS138 in RPMI medium without phenol red and including 10 
mmol/l HEPES and 10% fetal calf serum (Invitrogen). A Zeiss 
LSM510 meta confocal laser-scanning microscope was 
used, equipped with a temperature controlled CO2 incubator 
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(type S) and sample stage. For recording of oligo uptake, we 
used a PlanApochromatic 63×, 1.4 NA oil immersion DIC 
lens (Carl Zeiss, Jena, Germany).
Western blotting. DM1 patient 21/200 myoblasts or DM500 
mouse myotubes were transfected with PS147, PS58, PS146, 
PS260 or PS261 as indicated (200 nmol/l) or mock transfected 
and 72 hours later lysed in lysis buffer (TBS, 1% Nonidet P-40, 
1 mmol/l PMSF, and Protease Inhibitory Mixture (Roche)) on 
ice. Cleared lysates were separated on an 8% SDS/PAGE 
gel and transferred to PVDF (Amersham Pharmacia Biotech, 
 Piscataway, NJ). Blots were incubated with DMPK-specific 
antibody B7921 or anti-SIN1/Mapkap1 antibody (ab71152; 
Abcam, Cambridge, UK) and β-tubulin monoclonal antibody 
E7 (Developmental Studies Hybridoma Bank, University of 
Iowa, Iowa City, IA), followed by electrochemiluminescence 
detection. Quantification of signals was done using ImageJ 
software. Values for mock-treated samples were set at 100%.
Experiments using in vitro-transcribed triplet repeat RNA. 
(CUG)n and (CAG)n RNA was generated by in vitro tran-
scription of a hDMPK (CTG)90 DNA template carrying flank-
ing T7 and SP6 promoters. The hDMPK (CTG)90 template 
was generated by PCR using a hDMPK cDNA construct 
bearing a (CTG)90 repeat,50 T7-hDMPK forward primer: 
5′-GAATTTAATACGACTCACTATAGGGAGAACGGGGCTC-
GAAGGGT-3′ and SP6-hDMPK reverse primer: 5′-ATTTAG-
GTGACACTATAGAAGGGCGTCATGCACAAGAAA-3′ and 
sequenced to verify triplet repeat number. (CUG)90 and 
(CAG)90 RNAs were synthesized in presence of [α-32P]GTP, 
using the MEGAscript in vitro transcription kit (Applied Bio-
systems/Ambion, Austin, TX) according to the manufacturer’s 
protocol.
To confirm AON binding to expanded triplet repeat RNA, 
(CUG)90 RNA was incubated with a concentration series (1, 
10, and 100 μmol/l) of PS58 in 50 mmol/l Tris-HCl; pH 7.5 
and 25 mmol/l MgCl2 for 2 hours at 37 °C. Sample buffer was 
added to a final concentration of 50% deionized formamide 
and 30% glycerol and samples were run at room tempera-
ture on a denaturing polyacrylamide gel (5% acryl/bisacryl, 
8 mol/l urea) in 1× MOPS. Gels were dried and exposed to 
X-ray film (X-Omat AR; Kodak).
To reveal binding specificity, (CUG)90 and (CAG)90 RNAs 
were incubated with 100 μmol/l AONs in the presence of 50 
mmol/l Tris-HCl; pH 7.5, 50 mmol/l NaCl, 25 mmol/l MgCl2, 
and 1 mmol/l EDTA for 2 hours at 37 °C. Samples were next 
analyzed by electrophoresis as described above.
To examine RNase-H–dependent activity, (CUG)n RNA 
was dissolved in 50 mmol/l Tris-HCl; pH 7.5, 50 mmol/l KCl, 5 
mmol/l MgCl2, and 1 mmol/l DTT and incubated with 60–100 
μmol/l AON in the presence of 20 U/ml RNase-H for 1 hour 
at 37 °C. Samples were analyzed by electrophoresis as 
described above with the exception that the 1× MOPS run-
ning buffer was heated to 70 °C before start of electrophore-
sis to induce dissociation between AONs and (CUG)n RNA.
To examine intrinsic oligo catalytic activity, (CUG)n RNA 
was dissolved in 100 mmol/l Tris-HCl; pH 7.5, 100 mmol/l 
NaCl, and 1 mmol/l EDTA and incubated with 100 μmol/l 
AON for 2 hours at 37 °C in the presence of 3.5 or 25 
mmol/l MgCl2. Samples were analyzed by electrophoresis as 
described above.
Complement activation assay. The potency of AONs to acti-
vate the complement pathway was demonstrated using Li+ 
heparin plasma from cynomolgus monkeys (kindly provided 
by CIT, France) and Li+ heparin plasma from healthy human 
donors (Sanquin, Amsterdam, The Netherlands). AONs were 
added to plasma in various concentrations (25, 50, 150, 
and 300 μg/ml in a dilution of ~1:20 (volume AON/volume 
plasma)) and the samples were incubated at 37 °C for 30 
minutes. The reaction was terminated by putting the samples 
on ice and adding ice-cold diluents according to the manufac-
turer’s protocol (Quidel, San Diego, CA). Bb and C3a concen-
trations were determined by ELISA (Quidel). First generation 
oligonucleotide PS455 (ISIS 5132) was included as a positive 
control, as this oligo has been shown to activate the comple-
ment pathway.25
Statistical analysis. Northern blot and PCR signals were ana-
lyzed using an unpaired Student’s t-test or a one-way analysis 
of variance. All values in graphs are presented as the mean ± 
SEM. Pearson’s correlation was applied to evaluate whether 
a correlation exists between silencing efficacy and number of 
CTG triplets in hDMPK alleles in human myoblasts. Differences 
between groups were considered significant when P < 0.05: *P 
< 0.05; **P < 0.01; ***P < 0.001. Statistical analyses and sig-
moidal concentration curve fitting were performed with Graph-
Pad Prism 4 software (GraphPad Software, La Jolla, CA).
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